Dozens of drugs designed to target and clear beta-amyloid plaques in the brain have failed to prevent or halt the progression of Alzheimer’s disease….
UPDATE: 3 March 2024, 8:35 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Vaccines are considered one of the greatest innovations in medical history. Immunizations help train the body’s immune system to recognize and respond to a…
Human clinical trials kick off for Protollin, an experimental Alzheimer’s vaccine. After two decades of research and development, Brigham and Women’s Hospital has initiated…
The Centers for Medicare and Medicaid Services will limit Aduhelm coverage to only participants in approved clinical trials. UPDATE: 3 March 2024, 8:24 P.M….
Vaccines are one of the greatest medical advances in history. This strategy is now being applied to the treatment and prevention of Alzheimer’s. We…
Scientists have their eyes set on spotting Alzheimer’s early. The earlier the disease can be diagnosed, the better the chance that a combination of…
On the brink of a new year, a note from Being Patient Founder and Editor-in-Chief Deborah Kan. Dear readers, As I reflect on 2021,…
Alzheimer’s is a notoriously difficult disease to identify with certainty. By the time a patient receives a diagnosis, its pathology in the brain is…
What’s the difference between treating Alzheimer’s symptoms and modifying the disease? Despite decades of research, the underlying cause of Alzheimer’s continues to evade scientists….
UPDATE: 3 March 2024, 8:39 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Protollin, a new vaccine for Alzheimer’s that is administered nasally, heads to human clinical trials. Through the incredible power of our immune system, researchers…
Beta-amyloid plaques are a hallmark of Alzheimer’s, but researchers have long been puzzled about why these plaques can also be found in the brains…
New clinical trials on memory loss interventions are currently enrolling healthy participants with key Alzhemier’s biomarkers as young as 55 years old. Tau and…
The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…